This highlights the limited utility of ECMO as a “bridge to recovery” for non-transplant candidates with acute exacerbation of ILD, whether related to anti-MDA5 dermatomyositis or other ILD types. This evidence concerns the gene IFIH1 and interstitial lung disease.